Eli Total Current Liabilities vs Asset Turnover Analysis

LLY Stock

USD 737.20 3.69 0.50%

Eli Lilly financial indicator trend analysis is much more than just examining Eli Lilly latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Eli Lilly is a good investment. Please check the relationship between Eli Lilly Total Current Liabilities and its Asset Turnover accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Eli Lilly and. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis.

Total Current Liabilities vs Asset Turnover

Total Current Liabilities vs Asset Turnover Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Eli Lilly Total Current Liabilities account and Asset Turnover. At this time, the significance of the direction appears to have significant contrarian relationship.

The correlation between Eli Lilly's Total Current Liabilities and Asset Turnover is -0.29. Overlapping area represents the amount of variation of Total Current Liabilities that can explain the historical movement of Asset Turnover in the same time period over historical financial statements of Eli Lilly and, assuming nothing else is changed. The correlation between historical values of Eli Lilly's Total Current Liabilities and Asset Turnover is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Current Liabilities of Eli Lilly and are associated (or correlated) with its Asset Turnover. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Asset Turnover has no effect on the direction of Total Current Liabilities i.e., Eli Lilly's Total Current Liabilities and Asset Turnover go up and down completely randomly.

Correlation Coefficient

-0.29

Relationship Direction	Negative
Relationship Strength	Insignificant

View All Relationships

Total Current Liabilities

Total Current Liabilities is an item on Eli Lilly balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Eli Lilly and are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Asset Turnover

The ratio of net sales to average total assets, indicating how efficiently a company uses its assets to generate sales.

Most indicators from Eli Lilly's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Eli Lilly current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Eli Lilly and. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis.

At this time, Eli Lilly's Discontinued Operations is fairly stable compared to the past year. Sales General And Administrative To Revenue is likely to rise to 0.32 in 2024, whereas Selling General Administrative is likely to drop slightly above 5.7 B in 2024.

	2021	2022	2023	2024 (projected)
Gross Profit	21.0B	21.9B	27.5B	28.9B
Total Revenue	28.3B	28.5B	34.1B	35.8B

Gross Profit Total Revenue

Eli Lilly fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Intangible Assets	Other Current Liab	Short Term Debt	Accounts Payable	Property Plant And Equipment Gross	Common Stock Total Equity	Short Term Investments
Total Assets		0.92	0.94	0.11	0.76	0.83	0.08	0.21	0.99	0.45	0.13	0.94	-0.75	0.85	0.96	0.17	0.76	0.95	0.97	0.74	0.32	0.72	0.96	0.82	-0.13	-0.27
Short Long Term Debt Total	0.92		0.95	-0.24	0.61	0.97	-0.28	-0.06	0.91	0.33	-0.17	0.96	-0.91	0.9	0.93	0.19	0.71	0.98	0.88	0.82	0.23	0.76	0.95	0.86	-0.15	-0.51
Total Current Liabilities	0.94	0.95		-0.02	0.62	0.91	-0.09	0.0	0.92	0.36	-0.06	0.97	-0.78	0.76	0.94	-0.03	0.59	0.93	0.92	0.68	0.26	0.88	0.97	0.91	-0.16	-0.36
Total Stockholder Equity	0.11	-0.24	-0.02		0.33	-0.34	0.97	0.46	0.13	0.06	0.62	-0.1	0.47	-0.33	0.06	-0.36	-0.06	-0.19	0.09	-0.18	0.02	0.02	0.03	-0.07	0.01	0.75
Property Plant And Equipment Net	0.76	0.61	0.62	0.33		0.52	0.3	0.28	0.77	0.44	0.23	0.64	-0.46	0.64	0.69	0.29	0.86	0.67	0.7	0.62	0.33	0.38	0.68	0.51	-0.09	-0.01
Net Debt	0.83	0.97	0.91	-0.34	0.52		-0.4	-0.29	0.85	0.22	-0.38	0.93	-0.94	0.84	0.87	0.16	0.63	0.93	0.77	0.83	0.19	0.73	0.91	0.88	-0.1	-0.58
Retained Earnings	0.08	-0.28	-0.09	0.97	0.3	-0.4		0.57	0.09	0.05	0.73	-0.18	0.53	-0.31	0.03	-0.32	-0.06	-0.22	0.06	-0.21	-0.05	-0.05	-0.03	-0.2	0.01	0.81
Cash	0.21	-0.06	0.0	0.46	0.28	-0.29	0.57		0.11	0.42	0.96	-0.04	0.3	0.11	0.09	0.11	0.22	0.06	0.34	-0.22	0.11	0.0	-0.02	-0.21	-0.2	0.4
Non Current Assets Total	0.99	0.91	0.92	0.13	0.77	0.85	0.09	0.11		0.41	0.06	0.93	-0.78	0.85	0.95	0.2	0.77	0.94	0.92	0.8	0.3	0.68	0.96	0.82	-0.1	-0.26
Non Currrent Assets Other	0.45	0.33	0.36	0.06	0.44	0.22	0.05	0.42	0.41		0.24	0.37	-0.29	0.43	0.29	0.34	0.57	0.43	0.49	0.04	0.54	0.24	0.29	0.29	0.02	-0.39
Cash And Short Term Investments	0.13	-0.17	-0.06	0.62	0.23	-0.38	0.73	0.96	0.06	0.24		-0.14	0.45	-0.05	0.04	-0.04	0.07	-0.06	0.24	-0.28	-0.01	-0.02	-0.08	-0.29	-0.13	0.63
Net Receivables	0.94	0.96	0.97	-0.1	0.64	0.93	-0.18	-0.04	0.93	0.37	-0.14		-0.87	0.85	0.93	0.15	0.69	0.96	0.92	0.78	0.35	0.74	0.97	0.94	-0.19	-0.48
Common Stock Shares Outstanding	-0.75	-0.91	-0.78	0.47	-0.46	-0.94	0.53	0.3	-0.78	-0.29	0.45	-0.87		-0.89	-0.76	-0.44	-0.71	-0.89	-0.69	-0.84	-0.34	-0.5	-0.8	-0.8	0.04	0.73
Non Current Liabilities Total	0.85	0.9	0.76	-0.33	0.64	0.84	-0.31	0.11	0.85	0.43	-0.05	0.85	-0.89		0.81	0.53	0.86	0.95	0.83	0.81	0.32	0.46	0.8	0.66	-0.1	-0.55
Inventory	0.96	0.93	0.94	0.06	0.69	0.87	0.03	0.09	0.95	0.29	0.04	0.93	-0.76	0.81		0.07	0.68	0.93	0.93	0.75	0.24	0.77	0.96	0.83	-0.03	-0.24
Other Current Assets	0.17	0.19	-0.03	-0.36	0.29	0.16	-0.32	0.11	0.2	0.34	-0.04	0.15	-0.44	0.53	0.07		0.63	0.29	0.13	0.41	0.52	-0.38	0.05	0.02	0.07	-0.38
Other Stockholder Equity	0.76	0.71	0.59	-0.06	0.86	0.63	-0.06	0.22	0.77	0.57	0.07	0.69	-0.71	0.86	0.68	0.63		0.79	0.71	0.71	0.46	0.25	0.66	0.52	0.0	-0.38
Total Liab	0.95	0.98	0.93	-0.19	0.67	0.93	-0.22	0.06	0.94	0.43	-0.06	0.96	-0.89	0.95	0.93	0.29	0.79		0.93	0.8	0.31	0.69	0.94	0.83	-0.13	-0.49
Total Current Assets	0.97	0.88	0.92	0.09	0.7	0.77	0.06	0.34	0.92	0.49	0.24	0.92	-0.69	0.83	0.93	0.13	0.71	0.93		0.61	0.34	0.74	0.91	0.79	-0.18	-0.27
Intangible Assets	0.74	0.82	0.68	-0.18	0.62	0.83	-0.21	-0.22	0.8	0.04	-0.28	0.78	-0.84	0.81	0.75	0.41	0.71	0.8	0.61		0.15	0.37	0.79	0.7	-0.17	-0.4
Other Current Liab	0.32	0.23	0.26	0.02	0.33	0.19	-0.05	0.11	0.3	0.54	-0.01	0.35	-0.34	0.32	0.24	0.52	0.46	0.31	0.34	0.15		-0.01	0.28	0.38	-0.01	-0.32
Short Term Debt	0.72	0.76	0.88	0.02	0.38	0.73	-0.05	0.0	0.68	0.24	-0.02	0.74	-0.5	0.46	0.77	-0.38	0.25	0.69	0.74	0.37	-0.01		0.77	0.74	-0.19	-0.18
Accounts Payable	0.96	0.95	0.97	0.03	0.68	0.91	-0.03	-0.02	0.96	0.29	-0.08	0.97	-0.8	0.8	0.96	0.05	0.66	0.94	0.91	0.79	0.28	0.77		0.9	-0.17	-0.34
Property Plant And Equipment Gross	0.82	0.86	0.91	-0.07	0.51	0.88	-0.2	-0.21	0.82	0.29	-0.29	0.94	-0.8	0.66	0.83	0.02	0.52	0.83	0.79	0.7	0.38	0.74	0.9		-0.17	-0.47
Common Stock Total Equity	-0.13	-0.15	-0.16	0.01	-0.09	-0.1	0.01	-0.2	-0.1	0.02	-0.13	-0.19	0.04	-0.1	-0.03	0.07	0.0	-0.13	-0.18	-0.17	-0.01	-0.19	-0.17	-0.17		0.14
Short Term Investments	-0.27	-0.51	-0.36	0.75	-0.01	-0.58	0.81	0.4	-0.26	-0.39	0.63	-0.48	0.73	-0.55	-0.24	-0.38	-0.38	-0.49	-0.27	-0.4	-0.32	-0.18	-0.34	-0.47	0.14

Click cells to compare fundamentals

Eli Lilly Account Relationship Matchups

Eli Lilly fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	39.3B	46.6B	48.8B	49.5B	64.0B	67.2B
Short Long Term Debt Total	15.8B	16.6B	16.9B	16.2B	25.2B	26.5B
Total Current Liabilities	11.8B	12.5B	15.1B	17.1B	27.3B	28.7B
Total Stockholder Equity	2.6B	5.6B	9.0B	10.6B	10.8B	9.0B
Property Plant And Equipment Net	8.4B	8.7B	9.0B	10.1B	12.9B	6.8B
Net Debt	13.5B	12.9B	13.1B	14.2B	22.4B	23.5B
Retained Earnings	4.9B	7.8B	9.0B	10.0B	10.3B	9.5B
Cash	2.3B	3.7B	3.8B	2.1B	2.8B	3.1B
Non Current Assets Total	25.6B	29.2B	30.4B	31.5B	38.3B	40.2B
Non Currrent Assets Other	2.3B	3.5B	4.1B	4.3B	5.0B	2.9B
Cash And Short Term Investments	2.4B	3.7B	3.9B	2.2B	2.9B	3.7B
Net Receivables	5.5B	6.9B	8.1B	8.6B	11.3B	11.9B
Common Stock Shares Outstanding	935.7M	912.5M	911.7M	904.6M	903.3M	868.4M
Liabilities And Stockholders Equity	39.3B	46.6B	48.8B	49.5B	64.0B	67.2B
Non Current Liabilities Total	24.8B	28.3B	24.6B	21.6B	25.8B	27.1B
Inventory	3.2B	4.0B	3.9B	4.3B	5.8B	6.1B
Other Current Assets	2.5B	2.9B	2.5B	3.0B	149.5M	142.0M
Other Stockholder Equity	3.6B	3.7B	3.8B	3.9B	4.2B	2.3B
Total Liab	36.6B	40.8B	39.7B	38.7B	53.1B	55.8B
Total Current Assets	13.7B	17.5B	18.5B	18.0B	25.7B	27.0B
Intangible Assets	6.6B	7.5B	7.7B	7.2B	6.9B	7.3B
Other Current Liab	2.2B	2.8B	3.0B	13.7B	3.3B	3.7B
Short Term Debt	1.5B	8.7M	1.5B	1.5B	6.9B	7.2B
Accounts Payable	1.4B	1.6B	1.7B	1.9B	2.6B	2.7B
Property Plant And Equipment Gross	8.4B	8.7B	19.0B	20.4B	24.0B	25.2B
Accumulated Other Comprehensive Income	(6.5B)	(6.5B)	(4.3B)	(3.8B)	(4.3B)	(4.5B)
Common Stock Total Equity	661M	598.8M	598.2M	594.1M	534.7M	494.1M
Short Term Investments	101M	24.2M	90.1M	144.8M	109.1M	103.6M
Capital Stock	598.8M	598.2M	596.3M	594.1M	593.6M	544.7M
Common Stock	598.8M	598.2M	596.3M	594.1M	593.6M	544.7M
Other Liab	10.5B	11.0B	8.7B	6.1B	7.0B	5.5B
Other Assets	4.7B	9.3B	6.4B	7.1B	8.2B	4.2B
Long Term Debt	13.8B	16.6B	15.3B	14.7B	18.3B	19.2B
Treasury Stock	(60.8M)	(55.7M)	(52.7M)	(50.5M)	(44.2M)	(46.4M)
Property Plant Equipment	7.9B	8.7B	9.0B	10.1B	11.7B	8.5B
Good Will	3.7B	3.8B	3.9B	4.1B	4.9B	2.9B
Current Deferred Revenue	6.7B	8.1B	8.8B	14.5B	16.7B	17.5B
Noncontrolling Interest In Consolidated Entity	92.2M	183.6M	175.6M	125.6M	91.8M	141.7M
Retained Earnings Total Equity	13.9B	11.4B	4.9B	10.0B	11.5B	10.8B

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether Eli Lilly offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Eli Lilly's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Eli Lilly And Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Eli Lilly And Stock:

How To Invest In Eli

Details

Is Eli Stock a good investment?

Details

What is Eli Lilly's Net Worth?

Details

Largest Pharmaceuticals Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Eli Lilly and. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis.

You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..

Complementary Tools for Eli Stock analysis

When running Eli Lilly's price analysis, check to measure Eli Lilly's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Eli Lilly is operating at the current time. Most of Eli Lilly's value examination focuses on studying past and present price action to predict the probability of Eli Lilly's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Eli Lilly's price. Additionally, you may evaluate how the addition of Eli Lilly to your portfolios can decrease your overall portfolio volatility.

	Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
	Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities
	Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital
	Transaction History View history of all your transactions and understand their impact on performance
	Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
	Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios
	Stocks Directory Find actively traded stocks across global markets
	Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
	Economic Indicators Top statistical indicators that provide insights into how an economy is performing
	Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years
	Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum
	Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments

Is Eli Lilly's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Eli Lilly. If investors know Eli will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Eli Lilly listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

0.13

Dividend Share

4.52

Earnings Share

5.79

Revenue Per Share

37.908

Quarterly Revenue Growth

0.281

The market value of Eli Lilly is measured differently than its book value, which is the value of Eli that is recorded on the company's balance sheet. Investors also form their own opinion of Eli Lilly's value that differs from its market value or its book value, called intrinsic value, which is Eli Lilly's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Eli Lilly's market value can be influenced by many factors that don't directly affect Eli Lilly's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Eli Lilly's value and its price as these two are different measures arrived at by different means. Investors typically determine if Eli Lilly is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Eli Lilly's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Eli Total Current Liabilities vs Asset Turnover Analysis

Total Current Liabilities vs Asset Turnover

Total Current Liabilities vs Asset Turnover Correlation Analysis

Correlation Coefficient

Total Current Liabilities

Asset Turnover

Eli Lilly fundamental ratios Correlations

Eli Lilly Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Eli Lilly fundamental ratios Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

Complementary Tools for Eli Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Non Current Assets Total	+ 0.99	Total Assets
Total Liab	+ 0.98	Short Long Term Debt Total
Total Current Assets	+ 0.97	Total Assets
Net Debt	+ 0.97	Short Long Term Debt Total
Net Receivables	+ 0.97	Total Current Liabilities
Accounts Payable	+ 0.97	Total Current Liabilities

Common Stock Shares Outstanding	- 0.94	Net Debt
Common Stock Shares Outstanding	- 0.91	Short Long Term Debt Total
Total Liab	- 0.89	Common Stock Shares Outstanding
Non Current Liabilities Total	- 0.89	Common Stock Shares Outstanding
Common Stock Shares Outstanding	- 0.87	Net Receivables
Intangible Assets	- 0.84	Common Stock Shares Outstanding